Evidence map›Paper›PMID 30131506›Full record

ArticleScientific reports2018

Deletion of p75

Sally L Elshaer, Azza B El-Remessy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Modulation of p75International journal of molecular sciences · 2021
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Sally L ElshaerAugusta Biomedical Research Corporation, Augusta, GA, 30912, USA.
Azza B El-RemessyAugusta Biomedical Research Corporation, Augusta, GA, 30912, USA. Azza.El-Remessy@va.gov.ORCID 0000-0003-4386-1989
Augusta University · USUniversity of Tennessee Health Science Center · US

Funding

Molecular Mechanisms of diabetic retinopathyR01EY022408 · NEI · UNIVERSITY OF GEORGIA · PI EL-REMESSY, AZZA B · 2012 to 2016
$1.5M
American Heart Association (American Heart Association, Inc.) 15PRE22830019NEI NIH HHS R01 EY022408U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI) RO-1-EY-022408
6 · The paper itself

Abstract

Ischemic retinopathy is characterized by ischemia followed by retinal neovascularization (RNV) resulting in visual impairment. Given the role of neuron-secreted growth factors in regulating angiogenesis, we examined how genetic deletion of the neurotrophin receptor; p75

Indexed as

Gene DeletionAnimalsCarbazolesDisease Models, AnimalHumansHyperoxiaIndole AlkaloidsMiceNerve Growth FactorOxygenProtein PrecursorsProto-Oncogene Proteins c-aktReceptors, Nerve Growth FactorReceptor, trkARetinal NeovascularizationVascular Endothelial Growth Factor ACarbazolesIndole AlkaloidsKdr protein, mouseNerve Growth FactorNgfr protein, mouseOxygenpro-nerve growth factor, mouseProtein PrecursorsProto-Oncogene Proteins c-aktReceptors, Nerve Growth FactorReceptor, trkAstaurosporine aglyconeVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID30131506
PMCPMC6104090
OpenAlexW2887545977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.